vs
Side-by-side financial comparison of ECB Bancorp, Inc. (ECBK) and Foghorn Therapeutics Inc. (FHTX). Click either name above to swap in a different company.
ECB Bancorp, Inc. is the larger business by last-quarter revenue ($9.5M vs $9.2M, roughly 1.0× Foghorn Therapeutics Inc.). ECB Bancorp, Inc. runs the higher net margin — 27.3% vs -234.3%, a 261.6% gap on every dollar of revenue. On growth, Foghorn Therapeutics Inc. posted the faster year-over-year revenue change (223.8% vs 33.8%). Over the past eight quarters, Foghorn Therapeutics Inc.'s revenue compounded faster (35.3% CAGR vs 23.8%).
ECB Bancorp, Inc. (MD) is a US-based bank holding company. It offers a full suite of retail and commercial banking products including deposit accounts, consumer loans, commercial financing and wealth management solutions, primarily serving individuals and small-to-mid enterprises across local markets in Maryland.
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies targeting the chromatin regulatory system to treat various types of cancer and other severe diseases. It advances a diverse pipeline of targeted drug candidates, conducting internal R&D and strategic partnerships to serve global patient populations.
ECBK vs FHTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.5M | $9.2M |
| Net Profit | $2.6M | $-21.7M |
| Gross Margin | — | — |
| Operating Margin | 36.7% | -258.2% |
| Net Margin | 27.3% | -234.3% |
| Revenue YoY | 33.8% | 223.8% |
| Net Profit YoY | 79.5% | -11.1% |
| EPS (diluted) | $0.32 | $-0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.5M | $9.2M | ||
| Q3 25 | $8.8M | $8.2M | ||
| Q2 25 | $8.0M | $7.6M | ||
| Q1 25 | $6.9M | $6.0M | ||
| Q4 24 | $7.1M | $2.9M | ||
| Q3 24 | $6.6M | $7.8M | ||
| Q2 24 | $6.3M | $6.9M | ||
| Q1 24 | $6.2M | $5.0M |
| Q4 25 | $2.6M | $-21.7M | ||
| Q3 25 | $2.4M | $-15.8M | ||
| Q2 25 | $1.4M | $-17.9M | ||
| Q1 25 | $1.3M | $-18.8M | ||
| Q4 24 | $1.4M | $-19.5M | ||
| Q3 24 | $1.1M | $-19.1M | ||
| Q2 24 | $791.0K | $-23.0M | ||
| Q1 24 | $621.0K | $-25.0M |
| Q4 25 | 36.7% | -258.2% | ||
| Q3 25 | 37.0% | -226.9% | ||
| Q2 25 | 23.9% | -279.2% | ||
| Q1 25 | 24.9% | -385.0% | ||
| Q4 24 | 27.3% | -840.5% | ||
| Q3 24 | 23.3% | -305.5% | ||
| Q2 24 | 16.9% | -386.6% | ||
| Q1 24 | 13.4% | -558.3% |
| Q4 25 | 27.3% | -234.3% | ||
| Q3 25 | 27.7% | -194.4% | ||
| Q2 25 | 18.0% | -237.3% | ||
| Q1 25 | 18.7% | -316.4% | ||
| Q4 24 | 20.3% | -682.9% | ||
| Q3 24 | 17.2% | -244.9% | ||
| Q2 24 | 12.6% | -333.6% | ||
| Q1 24 | 10.0% | -495.4% |
| Q4 25 | $0.32 | $-0.35 | ||
| Q3 25 | $0.29 | $-0.25 | ||
| Q2 25 | $0.17 | $-0.28 | ||
| Q1 25 | $0.16 | $-0.30 | ||
| Q4 24 | $0.18 | $-0.23 | ||
| Q3 24 | $0.14 | $-0.31 | ||
| Q2 24 | $0.09 | $-0.45 | ||
| Q1 24 | $0.07 | $-0.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $82.8M | $80.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $171.9M | $-108.5M |
| Total Assets | $1.6B | $198.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $82.8M | $80.9M | ||
| Q3 25 | $201.9M | $89.3M | ||
| Q2 25 | $191.0M | $72.6M | ||
| Q1 25 | $143.7M | $61.0M | ||
| Q4 24 | $309.4M | $55.5M | ||
| Q3 24 | $114.8M | $57.7M | ||
| Q2 24 | $108.7M | $138.9M | ||
| Q1 24 | $109.8M | $79.3M |
| Q4 25 | $171.9M | $-108.5M | ||
| Q3 25 | $169.3M | $-89.7M | ||
| Q2 25 | $168.3M | $-76.7M | ||
| Q1 25 | $168.6M | $-61.7M | ||
| Q4 24 | $168.3M | $-45.5M | ||
| Q3 24 | $166.0M | $-28.3M | ||
| Q2 24 | $166.5M | $-14.3M | ||
| Q1 24 | $165.8M | $-97.5M |
| Q4 25 | $1.6B | $198.1M | ||
| Q3 25 | $1.6B | $205.0M | ||
| Q2 25 | $1.5B | $226.2M | ||
| Q1 25 | $1.5B | $258.7M | ||
| Q4 24 | $1.4B | $284.0M | ||
| Q3 24 | $1.4B | $308.4M | ||
| Q2 24 | $1.3B | $328.6M | ||
| Q1 24 | $1.3B | $255.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.2M | $-22.3M |
| Free Cash FlowOCF − Capex | $9.0M | — |
| FCF MarginFCF / Revenue | 94.7% | — |
| Capex IntensityCapex / Revenue | 2.2% | 0.0% |
| Cash ConversionOCF / Net Profit | 3.55× | — |
| TTM Free Cash FlowTrailing 4 quarters | $14.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.2M | $-22.3M | ||
| Q3 25 | $4.0M | $-18.9M | ||
| Q2 25 | $1.9M | $-21.0M | ||
| Q1 25 | $-631.0K | $-24.0M | ||
| Q4 24 | $6.2M | $-24.5M | ||
| Q3 24 | $861.0K | $-21.0M | ||
| Q2 24 | $1.4M | $-25.5M | ||
| Q1 24 | $-429.0K | $-29.3M |
| Q4 25 | $9.0M | — | ||
| Q3 25 | $4.0M | — | ||
| Q2 25 | $1.8M | $-21.0M | ||
| Q1 25 | $-649.0K | $-24.0M | ||
| Q4 24 | $6.2M | $-25.0M | ||
| Q3 24 | — | $-21.3M | ||
| Q2 24 | $1.3M | $-25.6M | ||
| Q1 24 | $-449.0K | $-29.4M |
| Q4 25 | 94.7% | — | ||
| Q3 25 | 44.9% | — | ||
| Q2 25 | 23.0% | -278.2% | ||
| Q1 25 | -9.4% | -403.2% | ||
| Q4 24 | 86.8% | -875.3% | ||
| Q3 24 | — | -273.0% | ||
| Q2 24 | 21.4% | -371.0% | ||
| Q1 24 | -7.2% | -583.1% |
| Q4 25 | 2.2% | 0.0% | ||
| Q3 25 | 0.8% | 0.0% | ||
| Q2 25 | 0.6% | 0.3% | ||
| Q1 25 | 0.3% | 0.5% | ||
| Q4 24 | 0.8% | 16.8% | ||
| Q3 24 | 0.0% | 4.0% | ||
| Q2 24 | 0.6% | 0.2% | ||
| Q1 24 | 0.3% | 2.0% |
| Q4 25 | 3.55× | — | ||
| Q3 25 | 1.65× | — | ||
| Q2 25 | 1.32× | — | ||
| Q1 25 | -0.49× | — | ||
| Q4 24 | 4.31× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | -0.69× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
